- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06261359
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
February 7, 2024 updated by: Qilu Pharmaceutical Co., Ltd.
A Phase II, Randomized, Double-blind, Multi-center, Placebo-Controlled Study of the Efficacy and Safety of CEND-1 in Combination With Chemotherapy as First-Line Therapy in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of CEND-1 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo as first-line treatment in patients with Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jianming Xu, M.D
- Phone Number: 13910866712
- Email: Jianmingxu2014@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- Chinese People's Liberation Army (PLA) General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18~80 years old, male or female;
- Locally advanced unresectable or metastatic PDAC confirmed by histopathology or cytopathology;
- Patients who have not received prior systemic therapy for locally advanced or metastatic pancreatic cancer;
- Patients with at least one measurable tumor lesion per RECIST v1.1;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Expected survival time ≥ 12 weeks;
- Patients who have adequate organ function;
- Female subjects who are not pregnant or not breastfeeding. A negative pregnancy test for females of childbearing potential within 7 days prior to first dosing. Male and female subjects of childbearing potential must agree to use highly effective method of contraception during the entire course of the study and within 180 days after the end of the study.
- Subjects participate voluntarily and sign informed consent.
Exclusion Criteria:
- Concurrent use of other anticancer drugs, including chemotherapy, targeted therapy, immunotherapy, or biologics;
- The patients who are known to be allergic to the investigatinal drug or its any excipient;
- Patients with the following conditions: myocardial infarction, severe/unstable angina, NYHA grade 2 or above cardiac dysfunction, and clinically significant supraventricular or ventricular arrhythmia requiring clinical intervention within 6 months before signing the ICF;
- Patients with high risk for gastrointestinal bleeding or abdominal bleeding as assessed by the investigator, such as tumor invasion of the gastro duodenum finger intestines, large blood vessels, etc.;
- Patients with symptomatic CNS metastasis, leptomeningeal metastasis, or spinal cord compression due to metastasis.
- Patients with other active malignant tumors within 3 years before signing the ICF. Patients with cured skin basal cell carcinoma or squamous cell carcinoma, carcinoma in situ of the cervix, carcinoma in situ of the breast ductal, and papillary thyroid cancer can be enrolled.
- Patients with human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis or co-infection with hepatitis B and C.
- Patients who require systemic antibiotics for ≥7 days within 4 weeks prior to first dose, or unexplained fever >38.5°C prior during screening or before first dose;
- Patients who participated in any other clinical studies;
- Patients with a known history of psychoactive drug abuse, alcohol abuse, or substance abuse; History of definitive neurological or mental disorder, including epilepsy or dementia;
- The patients with added risks associated with the study or may interfere with the interpretation of study results as determined by the investigator, or deemed unsuitable by the investigator and/or sponsor.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CEND-1+ nab-paclitaxel + gemcitabine
Participants will receive nab-paclitaxel 125mg/m2; CEND1 3.2mg/kg IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle.
Each cycle will be 28 days.
|
CEND-1 will be provided as concentrate for solution to be administered via IV injection.
Other Names:
Gemcitabine will be provided as solution to be administered via IV infusion.
Other Names:
Nab-paclitaxel will be provided as solution to be administered via IV infusion.
Other Names:
|
Placebo Comparator: Placebo+ nab-paclitaxel + gemcitabine
Participants will receive nab-paclitaxel 125mg/m2; placebo IV; and then Gemcitabine 1000mg/m2, on Day 1, 8 and 15 of each cycle.
Each cycle will be 28 days.
|
Gemcitabine will be provided as solution to be administered via IV infusion.
Other Names:
Nab-paclitaxel will be provided as solution to be administered via IV infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR)
Time Frame: Approximately 36 months
|
ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by investigator evaluation per RECIST 1.1.
|
Approximately 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Approximately 36 months
|
OS is defined as the duration from randomization to the time point when death occurs due to any cause.
|
Approximately 36 months
|
Progression Free Survival(PFS)
Time Frame: Approximately 36 months
|
PFS is defined as the duration from randomization to the first imaging confirmation of progressive disease per RECIST 1.1 by investigator evaluation or death due to any cause (whichever occurs first).
|
Approximately 36 months
|
6-month PFS rate
Time Frame: Approximately 36 months
|
6-month progression-free survival (PFS) rate.
|
Approximately 36 months
|
Duration Of Response (DOR)
Time Frame: Approximately 36 months
|
DOR is defined as the time from the date of the first response (CR/PR) until the date of progressive disease as assessed by investigator evaluation per RECIST 1.1 or death due to any cause (whichever occurs first).
|
Approximately 36 months
|
Disease Control Rate (DCR)
Time Frame: Approximately 36 months
|
DCR was defined as the percentage of confirmed CR, PR or stable disease at the best response as assessed by investigator evaluation per RECIST 1.1.
|
Approximately 36 months
|
Incidence of AEs, SAEs and treatment-emergent adverse events (TEAEs)
Time Frame: From the subject signs the ICF to 30 days after the last dose of study drug was administered.
|
Adverse events (AEs), serious adverse events (SAEs), treatment-emergent adverse events are included.
The investigator should carry out judgment for investigational drug correlation.
|
From the subject signs the ICF to 30 days after the last dose of study drug was administered.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 1, 2024
Primary Completion (Estimated)
April 1, 2025
Study Completion (Estimated)
October 1, 2026
Study Registration Dates
First Submitted
February 7, 2024
First Submitted That Met QC Criteria
February 7, 2024
First Posted (Estimated)
February 15, 2024
Study Record Updates
Last Update Posted (Estimated)
February 15, 2024
Last Update Submitted That Met QC Criteria
February 7, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
- Gemcitabine
Other Study ID Numbers
- CEND1-202
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma (PDAC)
-
Mayo ClinicRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Dana-Farber Cancer InstituteRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Neoplasm | PDAC | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Azienda Ospedaliera Universitaria Integrata VeronaRecruitingPDAC - Pancreatic Ductal AdenocarcinomaItaly
-
Tianjin Medical University Cancer Institute and...Not yet recruitingPDAC - Pancreatic Ductal Adenocarcinoma
-
Sun Yat-sen UniversityRecruitingPDAC - Pancreatic Ductal AdenocarcinomaChina
-
Cedars-Sinai Medical CenterRecruitingPDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
Qilu Hospital of Shandong UniversityCompletedPancreatic Ductal Adenocarcinoma (PDAC)China
-
Ruijin HospitalRecruitingPancreatic Ductal Adenocarcinoma, PDACChina
-
Ruijin HospitalRecruitingPancreatic Ductal Adenocarcinoma, PDACChina
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
Clinical Trials on CEND-1
-
Qilu Pharmaceutical Co., Ltd.Cend Therapeutics Inc.Recruiting
-
Australasian Gastro-Intestinal Trials GroupUniversity of SydneyActive, not recruitingPancreatic Ductal Adenocarcinoma | Metastatic Pancreatic CancerAustralia, New Zealand
-
Lisata Therapeutics, Inc.CompletedPancreatic Cancer | Pancreatic Ductal AdenocarcinomaAustralia
-
Anup KasiCend Therapeutics Inc.RecruitingColon Cancer | Pancreas Cancer | Digestive CancerUnited States
-
Orasis Pharmaceuticals Ltd.Completed
-
University of ThessalyCompleted
-
University of Sao Paulo General HospitalCompleted
-
Chulalongkorn UniversityCompletedAllergic RhinitisThailand
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre and other collaboratorsCompletedHypertriglyceridemiaCanada